Slide Background Image

Revolutionising EBV Prevention with a First-in-Class Oral Vaccine

Thermostable, self-administered vaccines developed with cutting-edge AI-driven antigen design

iosBio is developing transformative oral vaccines using proprietary platforms to tackle major infectious diseases. Our lead candidate, OraPro-EBV, targets Epstein-Barr Virus – a significant unmet need linked to Multiple Sclerosis, mononucleosis, and several cancers. Discover how our thermostable OraPro™ technology, Enhanced Surface Display (ESD), and AI-driven antigen design are creating the future of vaccination.

Addressing Critical Unmet Needs in Vaccination

Over 90% of adults are infected with Epstein-Barr Virus, driving diseases like multiple sclerosis and cancer with no approved vaccine available. Traditional vaccines face challenges with cold chain logistics, needle administration, and mucosal immunity. iosBio tackles these problems head-on

Advancing our Lead Oral EBV Vaccine

OraPro-EBV has shown outstanding preclinical results, inducing class-leading antibody responses against key viral targets. We are preparing for a Phase 1 clinical trial.

Proprietary Platforms Driving Innovation

OraPro™ platform

The OraPro™ vaccine platform delivers needle-free, thermostable vaccines orally, eliminating cold-chain dependencies, enhancing global accessibility and generates mucosal & systemic immunity through self-administered capsules.

Enhance Surface Display (ESD™) platform

iosBio’s patented ESD™ technology significantly enhances antigen visibility to the immune system, driving stronger, faster, and longer-lasting immune responses compared to conventional methods.

AI-Assisted Antigen Design

Leveraging advanced artificial intelligence, iosBio accelerates vaccine development by optimizing antigen design for maximum immunogenicity and protection, drastically reducing time from discovery to delivery.

Partner with Us to Transform Vaccination

We are currently raising £12-30m to advance OraPro-EBV into the clinic. Join us in addressing a significant market opportunity and changing the future of global health.

Follow us

Keep up to date with our news and find out more about investment opportunities with iosBio.

The team of doctors and scientists at iosBio believe that the next great leap forward in immunization will be oral delivery

Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.

Contact us on

info@iosbio.com / 01444 241911

or fill out the form below.





    We will not, in any circumstances share your personal information with other individuals or organizations without your permission.